Arbutus Biopharma vs Nuvation Bio
Nuvation Bio is the larger business, with $62.9m of revenue in fiscal 2025 against $14.1m for Arbutus Biopharma (4.5 times as much). Nuvation Bio grew faster (699.0% against 128.2%). Arbutus Biopharma kept more of each dollar of sales as profit: a net margin of -237.9% against -325.3%. Arbutus Biopharma carries less debt relative to equity (0.0% against 17.3%).
| Latest fiscal year | Arbutus BiopharmaABUS, 2025 | Nuvation BioNUVB, 2025 |
|---|---|---|
| Revenue | $14.1m | $62.9m |
| Revenue growth | 128.2% | 699.0% |
| Net income | −$33.5m | −$205m |
| Operating margin | -271.0% | -338.7% |
| Net margin | -237.9% | -325.3% |
| Return on equity | -38.5% | -53.2% |
| Free cash flow | −$39.6m | −$181m |
| Cash | $18.0m | $164m |
| Total debt | $0 | $52.9m |
| Debt to equity | 0.0% | 17.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 298 |
| Market value | $791m | $1.59bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 16 sales |